2bind GmbH Launches Antibody Unit with Appointment of Dr. Vera Molkenthin as Director
January 2023 – 2bind GmbH announces the launch of its Antibody Unit and the appointment of Dr. Vera Molkenthin as its Director. Dr. Molkenthin brings extensive experience in antibody discovery and development, having previously served as Head of Antibody Discovery at Affimed AG and Chief Scientist at AbCheck s.r.o.
This appointment represents a significant expansion of 2bind’s capabilities, enabling the company to serve clients in the antibody market with its high-quality biophysical research services. Dr. Molkenthin is a strong advocate for the early integration of biophysical analysis and techniques in antibody discovery and development, recognizing their crucial role in ensuring successful outcomes.
“We are delighted to have Dr. Molkenthin lead our new Antibody Unit,” said Dr. Thomas Schubert, CEO of 2bind GmbH. “Her expertise and passion for applying biophysics to antibody research align perfectly with our vision. We are confident that under her management, 2bind will evolve to a trusted partner for clients seeking to accelerate their antibody development programs.”
